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C Michael Cotten7, Monica Malian1, Pablo J Sanchez8, Satyan Lakshminrusimha9, Leif D Nelin10,
Krisa P Van Meurs11, Rebecca Bara1, Shampa Saha12, Abhik Das13, Dennis Wallace13, Rosemary D Higgins14,
Seetha Shankaran1 and for the Eunice Kennedy Shriver National Institute of Child Health and Human Development
Neonatal Research NetworkAbstract
Background: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of
neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of
infants. Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1) have been reported to be effective selective pulmonary
vasodilators. The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of
inhaled PGE1 (IPGE1) in NHRF.
Methods: Two pilot multicenter phase II RCTs are included in this report. In the first pilot, late preterm and term
neonates with NHRF, who had an oxygenation index (OI) of ≥15 and <25 on two arterial blood gases and had not
previously received INO, were randomly assigned to receive two doses of IPGE1 (300 and 150 ng/kg/min) or
placebo. The primary outcome was the enrollment of 50 infants in six to nine months at 10 sites. The first pilot
was halted after four months for failure to enroll a single infant. The most common cause for non-enrollment
was prior initiation of INO. In a re-designed second pilot, co-administration of IPGE1 and INO was permitted.
Infants with suboptimal response to INO received either aerosolized saline or IPGE1 at a low (150 ng/kg/min) or
high dose (300 ng/kg/min) for a maximum duration of 72 hours. The primary outcome was the recruitment of
an adequate number of patients (n = 50) in a nine-month-period, with fewer than 20% protocol violations.
Results: No infants were enrolled in the first pilot. Seven patients were enrolled in the second pilot; three in the
control, two in the low-dose IPGE1, and two in the high-dose IPGE1 groups. The study was halted for recruitment
futility after approximately six months as enrollment targets were not met. No serious adverse events, one minor
protocol deviation and one pharmacy protocol violation were reported.
Conclusions: These two pilot RCTs failed to recruit adequate eligible newborns with NHRF. Complex
management RCTs of novel therapies for persistent pulmonary hypertension of the newborn (PPHN) may require
novel study designs and a longer period of time from study approval to commencement of enrollment.
Trial registration: ClinicalTrials.gov: Pilot one: NCT number: 00598429 registered on 10 January 2008. Last
updated: 3 February 2011.
Pilot two: NCT number: 01467076 17 October 2011. Last updated: 13 February 2013.
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Clinical trialBackground
Neonatal hypoxemic respiratory failure (NHRF) is usu-
ally associated with widespread vasoconstriction of the
pulmonary microvasculature, giving rise to intra- and
extra-pulmonary shunting and profound hypoxemia.
Due to the delay in the physiologic fall in pulmonary
vascular resistance, it is also known as persistent pul-
monary hypertension of the newborn (PPHN). The goal
of therapy is to decrease the regional pulmonary vascular
resistance of ventilated lung areas, thus decreasing
intrapulmonary shunting and selectively reducing the
pulmonary-artery pressure without causing systemic
vasodilation. Intravenously administered vasodilators
lack pulmonary selectivity leading to systemic side
effects. Inhaled nitric oxide (INO), a selective pulmon-
ary vasodilator, has revolutionized the treatment of re-
spiratory failure in the newborn. However, there is lack
of sustained improvement in 30 to 46% of infants [1-4].
Moreover, INO requires specialized delivery systems,
making the treatment expensive.
Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1)
have been reported to be effective selective pulmonary
vasodilators in animals, adults, and preterm and term
newborns [5-15]. Compared to PGI2, PGE1 has a shorter
half-life, lower acid dissociation constant (pKa, 6.3 ver-
sus 10.5), bronchodilator action, and anti-proliferative
and anti-inflammatory effects on the alveolar, interstitial,
and vascular spaces of the lung [10,16-20]. In addition,
PGE1 is readily available in pharmacies of hospitals with
neonatal services and has a proven safety record from its
intravenous use in ductal-dependent cardiac anomalies.
Prostaglandin nebulization can be performed without
the sophisticated technical equipment needed for INO
and hence is less expensive. Prostaglandins and nitric
oxide relax the vascular smooth muscle through two dif-
ferent second-messenger systems; therefore, in combin-
ation, INO and inhaled PGE1 (IPGE1) may have a
synergistic effect [21].
We reported the safety and feasibility of short-term
administration of IPGE1 in an un-blinded phase I/II
dose-escalation single center study [12] suggesting the
need for placebo-controlled randomized studies to es-
tablish the efficacy and safety of this drug for NHRF. In
that study, four doses ranging from 25 to 300 ng/kg/min
were tested for a maximum duration of three hours. The
purpose of the two studies included in this report was to
determine the feasibility of conducting a future large
randomized control trial (RCT) to evaluate the safetyand efficacy of prolonged IPGE1 at high-volume level
III to IV neonatal intensive care units (NICUs) within
the National Institute of Child Health and Human
Development (NICHD) Neonatal Research Network
(NRN).
Methods
Pilot one: a randomized clinical trial of inhaled PGE1 in
neonatal hypoxemic respiratory failure
Following the availability of INO for the treatment of
NHRF, several interventional clinical trials for NHRF
were halted prematurely for lack of enrollment [22-25].
Therefore, we sought to quantify the number of poten-
tially eligible patients and perform a pilot trial before
embarking upon a RCT of IPGE1. Late preterm and
term infants with NHRF who had an oxygenation index
(OI) (OI =mean airway pressure (MAP) × fractional in-
spired oxygen concentration (FiO2) × 100/arterial oxygen
tension (PaO2)) ≥15 and <25 on two arterial blood gases
(ABGs) and had not previously received INO were eli-
gible for the study. Infants would be randomly assigned
to receive two doses of IPGE1 (300 and 150 ng/kg/min)
or placebo over a maximum duration of 72 hours. The
primary outcome was the ability to enroll 50 infants in
six to nine months at 10 sites, without excessive proto-
col violations or adverse effects. Secondary outcome var-
iables included the definition of optimal dose and
duration of treatment with the study aerosol, the need
for INO or extra-corporeal membrane oxygenation
(ECMO) mortality, and duration of mechanical ventila-
tion, O2 administration, and INO administration.
The research study was approved by the institutional re-
view boards (IRBs) of all participating sites (see Additional
file 1). The first pilot RCT was halted after four months
for failure to enroll any infants. The most common
cause for inability to enroll infants was the rapidly
changing condition of the infants, resulting in prior ini-
tiation of INO in transport or soon after admission.
The next most frequent causes of inability to recruit in-
fants were lack of an arterial line and hypothermia
treatment for neonatal encephalopathy, both of which
were exclusion criteria.
Pilot two: a randomized clinical trial of inhaled PGE1 in
neonates with sub-optimal response to inhaled nitric
oxide
After evaluating the causes for lack of enrollment in
the first pilot, we determined that co-administration of
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impact on study feasibility, while allowing us to test for syn-
ergy between INO and IPGE1. In addition, we elected to
include infants receiving therapeutic hypothermia, as this
was now standard therapy in participating centers.
In order to design and meaningfully interpret the data
from the second pilot RCT in a manner that would be
most helpful for designing the main trial, we created a
definition of the primary outcome and conducted sample
size calculations for the main trial. Using the composite
outcome of need for ECMO or death as the most concrete
clinically meaningful outcome for the future main trial, a
sample size of 149 patients per group would be required
to detect a 16% absolute risk reduction in the composite
outcome of ECMO or death from 50% in the control arm
to 34% in the study arm, with α of 0.05, a power of 80%,
and a two-tailed test. To get an estimate of the number of
infants in the NRN sites that might be eligible for the
main trial, we queried all NRN sites. Between 2009 and
2010, 775 infants received INO for NHRF in 17 sites in
the NRN; 30 to 35% met the composite outcome of death
or ECMO and 10 to 13% died without receiving ECMO.
Based on these numbers, it would be feasible to perform
the main trial of IPGE1 in NHRF over three years or less.
Study eligibility was modified in the second pilot to in-
clude infants who had a suboptimal response to INO de-
fined as an OI of ≥15 on any two arterial blood gases,
obtained 15 minutes to 12 hours apart, and during the first
72 hours of INO use. The research study was approved by
the IRBs of all participating sites and informed parental
consent was obtained for all enrolled infants once eligibility
was confirmed and before institution of study intervention.
Subjects
Late preterm (34 0/7 to 36 6/7 weeks’ gestation) and
term infants at less than or equal to seven days postnatal
age, undergoing conventional ventilation (CNV) or
high-frequency oscillatory ventilation (HFOV) for NHRF
(including perinatal aspiration syndrome, suspected or
proven pneumonia or sepsis, respiratory distress syn-
drome, idiopathic PPHN, or suspected pulmonary hypo-
plasia), and with a suboptimal response to INO were
eligible. An indwelling arterial line was a requisite for
study participation, as was informed parental consent.
Exclusion criteria included the decision not to provide
full treatment, a known structural congenital heart dis-
ease except patent ductus arteriosus and atrial or ven-
tricular level shunts, congenital diaphragmatic hernia,
and thrombocytopenia (platelet count <80,000/μl) unre-
sponsive to platelet transfusion.
Study procedures
There were three arms to the study: low-dose IPGE1
(150 ng/kg/min), high-dose IPGE1 (300 ng/kg/min), andplacebo (aerosolized saline). The two doses of IPGE1 were
selected on the basis of the results of the pre-clinical tox-
icity study and the phase I/II open label study of IPGE1 in
NHRF [12]. Eligible infants were centrally randomized by
telephone using permuted block randomization. The
IPGE1 was double-masked. Only the participating center’s
pharmacist was aware of the infant’s assigned group.
PGE1 solution for aerosolization was prepared from syn-
thetic PGE1 (Prostin VR (Alprostadil) 500 μg/ml in 1 ml
dehydrated ethanol, Pfizer, New York, NY, USA) by dilu-
tion in sterile 0.9% saline (Sodium Chloride 0.9% Injection
USP, Hospira Inc., Lake Forest, IL, USA). Fresh solutions
were prepared every 24 hours. Aerosol administration
began with a PGE1 dosage of either 300 or 150 ng/kg/min
diluted in 4 ml preservative-free sterile normal saline/hr
in study patients, and 4 ml sterile normal saline/hr in
control patients. The study medication was delivered
using a syringe pump into the nebulizer chamber of the
MiniHeart low flow jet nebulizer (WestMed Inc., Tucson,
Arizona, United States) (Figure 1). The nebulizer was
placed approximately 50 cm from the endotracheal tube
for CNV, and approximately 35 cm from the endotracheal
tube in HFOV, based on bench studies to determine the
emitted dose [26]. The nebulizer chamber was primed
with 2 ml of study medication at study aerosol initiation.
For weaning purposes, normal saline was administered
using a second syringe pump with a Y-connection into the
nebulizer chamber with increasing dose as the study drug
aerosol dose was decreased, such that the total volume
delivered was always 4 ml/hour. During aerosol administra-
tion, FiO2 delivered in the gas flow through the nebulizer
was matched to that delivered in the ventilator circuit.
Conventional management including ventilation, he-
modynamic support, and sedation were optimized prior
to randomization as per usual care at site. Treatment
with INO was recommended if an OI ≥25 was docu-
mented on two consecutive ABGs at least 15 minutes
apart; however, depending on institutional practice,
treatment with INO could be instituted at an OI <25
[4,25]. It was recommended that an echocardiogram and
cranial sonogram be obtained prior to, or soon after, the
initiation of INO to rule out structural heart lesions,
establish the presence of pulmonary hypertension, and
evaluate for intracranial hemorrhage.
Response to study medication
Arterial blood gas analysis was performed 60 ± 15 minutes
after study aerosol initiation. Response was defined on the
basis of an increase in PaO2 (mmHg) above baseline after
60 ± 15 minutes exposure to the study aerosol as full
(≥20), partial (10 to 19) or no (<10) increase in PaO2. All
infants were continued on the assigned study aerosol
regardless of initial response until they weaned off, met
treatment failure criteria, or completed 72 hours of study
Figure 1 Diagram of nebulizer setup in neonatal ventilator circuit. Figure legend: ETT, endotracheal tube; INO, inhaled nitric oxide; CMV,
conventional mechanical ventilation; HFV, high frequency ventilation; IPGE1, inhaled PGE1 (Pfizer, New York, NY, USA).
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four ± two hours and every 12 ± two hours thereafter.
Additional blood gases were obtained as clinically indicated.
After the initial 60 ± 15 minutes observation period, thera-
peutic decisions were left to the clinical team.
Primary outcome
The primary aim of the study was the ability to recruit an
adequate number of patients (n = 50) in a nine-month-
period without excessive (more than 20%) protocol
violations.
Secondary outcomes
Secondary outcomes included improvement in PaO2 and
OI at 60 ± 15 minutes and four ± two hours after study
aerosol initiation; need for ECMO; death; combined out-
come of need for ECMO or death in the first 120 days
of life; need for supplemental O2 at 28 days of life; dur-
ation of INO, mechanical ventilation, supplemental oxy-
gen, and hospitalization; and occurrence of intracerebral
hemorrhage, intraventricular hemorrhage, periventricu-
lar hemorrhagic infarction, cystic leukomalacia, areas of
low attenuation in the white matter (edema or ischemia),
atrophy, and ventriculomegaly.
Treatment failure criteria
Treatment failure was defined as an acute deterioration
on initiation of, or during administration of, the study
aerosol with an absolute fall in pulse oximeter O2 satur-
ation (SPO2) by more than 10% for over 10 minutes, or
an absolute SPO2 of less than 85%. Mechanical causes,including pneumothorax or plugged or malpositioned
endotracheal tube (ETT) needed to be excluded. It was rec-
ommended that ECMO be considered in infants with an
OI >40, or an alveolar arterial PaO2 gradient >620 mmHg
for eight hours, a PaO2 < 40 to 50 mmHg for two to four
hours, or if institutional guidelines were met.
Weaning of study aerosol
A weaning algorithm was proposed for the study aerosol
to avoid a potential drop in PaO2. For any given weaning
time point, the dose was halved and weaning was
attempted only if the PaO2 was >60 torr. The first weaning
attempt was at 12 ± two hours. Further weaning attempts
were mandated at 12 ± two hour intervals. Total duration
of study aerosol administration could not exceed 72 hours.
Weaning to the third dose had to be accomplished by
48 hours on study aerosol.
Weaning of ventilator during study
Once the study aerosol was initiated, attempts to wean
INO dose and/or ventilator settings were protocol-driven
and every 12 hours or more frequently as deemed appro-
priate by the clinical team.
Monitoring of study aerosol administration
Enrolled infants were monitored continuously throughout
study aerosol administration for possible adverse effects of
PGE1, including hyperthermia (>38°C), bradycardia (heart
rate <70/min, arrhythmia, hypotension, seizures, bleeding
tendency, pulmonary hemorrhage, diarrhea, and seizures.
Study aerosol was weaned if hypotension or arrhythmia
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borns enrolled in the study were clinically evaluated for
signs and symptoms of patent ductus arteriosus (PDA at
well-defined time points (three ± one and seven ± one days
after discontinuation of the study medication and within
one week before discharge).
Protocol violations
Protocol violations included: wrong study aerosol admin-
istered; wean to dose three not completed by 48 +/− four
hours; study aerosol given for more than 72 +/− four
hours; and unmasking of the study aerosol.
Sample size
The pilot RCTs were primarily designed to evaluate the
feasibility and safety of prolonged IPGE1 administration
and determination of optimal dose in 50 patients re-
cruited at high-volume sites within the NRN. Compari-
son of the combined IPGE1 groups (n = 100) with the
control group (n = 50) would have a power of 76.9% to
detect a difference of 16% absolute risk reduction in the
composite outcome of ECMO or death, from 50% in the
control arm to 34% in the study arm, with α of 0.25 and
a two-tailed test. The higher type I error rate could erro-
neously lead to a conclusion of efficacy of IPGE1 but
would not increase the risk of missing an efficacious
treatment [27-29]. While statistically significant evidence
of treatment efficacy was unlikely in these small pilot tri-
als, we expected a relative risk of 67% (range: 50 to 80%)
for the treatment compared to the control arm for the
combined outcome of need for ECMO or death in 50
patients recruited over a time period of nine months to
be able to justify embarking upon the full-scale RCT.
Data Safety Monitoring Committee
The NICHD NRN Data Safety Monitoring Committee
(DSMC) monitored the progress of the trial for feasibility
and safety. Feasibility was defined a priori as the ability to
recruit at least four subjects per month over any rolling
three-month-period once 50% of the participating sites
had IRB approval; and six subjects per month over any
rolling three-month-period once 75% of the participating
sites had IRB approval. Given those accrual targets, if
fewer than 20 subjects had been enrolled in the six-
month-period after at least 75% of the sites had achieved
IRB approval, the DSMC could recommend that the trial
be stopped for futility.
Results
The second pilot was undertaken because no infants could
be enrolled in the first pilot; factors that hindered feasibil-
ity of the first pilot guided the study design of the second
pilot. Detailed results for the second pilot RCT are dis-
cussed in the following. A total of 10 sites participated inthe second pilot RCT. There was a lag from 33 to up to
90 days between IRB approval and site readiness to enroll
patients due to the complexity of education regarding drug
preparation and administration (Figure 2). Enrollment was
halted for lack of feasibility after approximately six months;
at that time, only seven patients had been enrolled.
During the study period, 46 infants were screened at eight
sites; 14 met eligibility criteria and seven were randomized
(50%) (Figure 3). The reasons for non-enrollment were:
parent unavailable or refused consent (three), met ECMO
criteria (three), or cardiorespiratory arrest (one).
Of the seven infants randomized, three received aer-
osolized saline, and two each received high-dose and
low-dose IPGE1. Aggregate data are presented for the
control group and the two IPGE1 groups combined be-
cause of the small numbers of subjects in each group
(Tables 1 and 2, Figures 4 and 5). The small numbers
precluded formal statistical testing. Detailed individual
patient data are presented in Table 3.
Delivery room characteristics of the enrolled infants in
the control group and the two IPGE1 groups combined are
presented in Table 1. Of note, all four infants assigned to
low- or high-dose IPGE1 were intubated in the delivery
room; three of these infants also received chest compres-
sions. None of the infants in the control group were intu-
bated or received chest compressions in the delivery room.
The underlying cause of NHRF was meconium aspir-
ation syndrome in five infants and idiopathic in two in-
fants; both infants with idiopathic NHRF were randomized
to the control group (Table 2). Postnatal age at the start of
INO ranged from two to 28 hours (Figure 4a). Duration of
treatment with INO prior to start of study aerosol ranged
from 3.5 to 23.5 hours, with the mean and median values
being higher for infants in the combined IPGE1 groups.
Infants were randomized to the study at an age range
of 7.1 to 58.3 hours; all infants in the control group
were >24 hours of age at time of randomization,
whereas three of the four infants randomized to low- or
high-dose IPGE1 were <16 hours of age (Figure 4b).
All infants had a trial of HFOV; five of the seven infants
were receiving HFOV and two were receiving conventional
mechanical ventilation at the time of randomization. All
seven infants received fluid boluses prior to randomization,
six infants received dopamine with or without dobutamine,
and three infants received milrinone before randomization
(Tables 2 and 3). Two infants in the control group received
milrinone both before and during study aerosol administra-
tion; in one infant in the IPGE1 group, milrinone was dis-
continued 18 hours after study aerosol initiation. Only one
infant received sildenafil before randomization; this infant
belonged to the control group and received concurrent mil-
rinone. All infants received sedation and/or analgesia, and
five of the seven received neuromuscular blockade. Four of
the seven infants received steroids before randomization.
Sites
skee
w
ni
ydutsfotrats
morf
e
miT
Figure 2 Timeline of Institutional Review Board (IRB) approval and readiness to enroll patients at various sites.
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INO. Data on the first OI ≥15 were available in six of
the seven enrolled infants; four of the six infants had OI
≥29 (highest OI: 99). OI on the first qualifying arterial
blood gas ranged from 16 to 69, with five of the seven
infants having OI ≥25. OI on the second qualifying ar-
terial blood gas ranged from 20 to 44, with six of the
seven infants having OI ≥25. All seven infants had at
least one documented OI >25, with six infants having
OI >35 prior to starting the study aerosol. The interval
between the first and second qualifying arterial blood
gas ranged from one to nine hours. The time from
randomization to study aerosol initiation ranged from
3.0 to 20.0 hours, with the interval being less than six in
all infants in the control group and more than six hours
in all infants in the combined IPGE1 groups (Figure 4c).Figure 3 Flow diagram of infants.The time from randomization to study aerosol initi-
ation ranged from 1.1 to 2.9 hours, with all infants in
the control group receiving study aerosol within
1.5 hours of randomization and all infants in the IPGE1
group receiving it after 1.5 hours (Figure 4d).
An echocardiogram was performed in all seven enrolled
infants before study aerosol initiation. PDA was visualized
in five infants, with direction of shunting being right to
left or bidirectional in three, left to right in one, and no
shunt documented in one.
Only one infant met the criteria for a complete response
based on the one-hour ABG and this infant belonged to
the control group. On the ABG obtained four hours after
the start of the study aerosol, there was improvement in
oxygenation in all three groups compared to the ABG ob-
tained after 60 minutes (mean change in PaO2 being 30,
Table 1 Delivery room characteristics of enrolled infants
Placebo n = 3 PGE1 n = 4
Maternal age mean, years (SD) 32.3 (6.8) 32.3 (9.4)
Outborn, n 3 3
Delivery by cesarean section, n 2 3
Birth weight mean, grams (SD) 3,590 (616) 3,425 (220)
Postmenstrual age mean, weeks (SD) 39.3 (1.5) 39.8 (0.5)
Apgar Score <3 at 1 minutes, n 0a 4
Apgar Score <3 at 5 minutes, n 0a 3
Intubation in the delivery room, n 0 4
Chest compressions in the delivery room, n 0 3
aData missing for one subject. Outborn - born at an institution other than
center where study intervention was administered.
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IPGE1 groups, respectively). The duration of treatment
with study aerosol ranged from 10 to 72 hours (Table 3).
All seven enrolled infants survived. Six infants received
ECMO; five of these received ECMO within 24 hours of
discontinuation of the study aerosol. During study aerosol
administration, acute deterioration was noted in three in-
fants, two in the low-dose and one in the high-dose IPGE1
group, at 10, 36, and 34 hours of age, respectively. The
first wean of the study aerosol had been attempted in two
of these infants and was successful in one infant.
All enrolled infants were closely monitored for prede-
fined adverse events. The lowest mean blood pressureTable 2 Status at randomization
Primary diagnosis (n)
Idiopathic
Aspiration syndrome
Age at start of INO (hours) mean, (SD)
Duration of INO before study aerosol (hours) mean, (SD)
Interval between first OI ≥15 and study aerosol (hours) mean, (SD)
Interval between first and second qualifying blood gases (hours) mean, (SD)
Interval from randomization to study gas initiation (hours) mean, (SD)
Age at randomization (hours) mean, (SD)
OI on baseline ABG mean, (SD)
Therapies prior to randomization (n):
Volume support
Vasopressor support
Sedation or analgesia
Neuromuscular blockade
Alkalosis
Surfactant
aData missing for one subject. ABG, arterial blood gas; INO, inhaled nitric oxide; OI,recorded during study aerosol administration was 37, 43,
and 45 mmHg in the control, low-dose, and high-dose
IPGE1 groups, respectively (Table 3, Figure 5). The high-
est heart rate recorded during study aerosol administra-
tion was 200, 131, and 142 bpm in the control, low-dose,
and high-dose IPGE1 groups, respectively. The highest
temperature recorded during study aerosol administration
was 38.2, 33.6, and 33.7°C in the control, low-dose, and
high-dose IPGE1 groups, respectively. Two adverse events
were reported during the study and nether was attributed
to the study aerosol. One infant in the control group
developed transient, self-resolved mild fever within five
minutes of starting the study aerosol, which was com-
pletely resolved within six hours after onset. One infant in
the control group developed moderate hypotension
66 hours after initiation of the study aerosol. It was com-
pletely resolved within an hour of its onset. All enrolled
infants were carefully clinically monitored for signs of
PDA after study aerosol discontinuation. None of the in-
fants had clinical signs of failure secondary to PDA
prompting an echocardiogram. One infant (in the high-
dose IPGE1 group) developed seizures later in the hospital
course, but the infant was not receiving study aerosol at
that time. No protocol violations were reported during the
study. There was one minor protocol deviation (ABG ob-
tained >60 ± 15 minutes after aerosol initiation) and one
pharmacy protocol violation (infant incorrectly received
150 ng/kg/min instead of the assigned 300 ng/kg/min
dose of PGE1; this was recognized on the 2nd day of study
aerosol administration).Placebo n = 3 PGE1 n = 4
2 0
1 4
26.6 (2.1)a 7.9 (9.4)
8.0 (6.0)a 13.4 (7.2)
4.2 (1.2) 12.2 (5.6)
2.4 (1.2) 4.7 (3.0)
1.2 (0.08) 2.3 (0.5)
41.7 (15.4) 19.0 (8.2)
26.0 (9.5) 23.8 (17.3)
3 4
3 3
3 4
2 3
2 1
3 2
oxygenation index.
(a) (b)
(c) (d)
INO Inhaled nitric oxide
OI    Oxygenation index
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Figure 4 Boxplots of timeline of events prior to initiation of study aerosol in control and combined IPGE1 groups (low-dose and
high-dose IPGE1). INO, inhaled nitric oxide; OI, oxygenation index. (a) Age at INO start (hours; (b) Age at randomization (hours); (c) Interval from
1st OI > 15 and start of study aerosol (hours); (d) Interval from randomization to start of study aerosol (hours).
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We assessed the feasibility of two pilot RCTs to evaluate
the use of two doses of IPGE1 in critically ill neonates with
NHRF and were unable to recruit sufficient eligible sub-
jects in the time period allowed. No infants were recruited
in the first pilot. The second pilot was designed taking into
account factors that hindered the feasibility of the first
pilot. We demonstrated that continuous administration of
aerosols was feasible in the second pilot. Of the 46 infants
screened in this second pilot, only 14 met the eligibilityFigure 5 Profile of temperature, heart rate, and mean blood pressure
IPGE1 groups (low-dose and high-dose IPGE1). Solid line with solid squa
represents subjects receiving IPGE1 (combined data for low-dose and high-criteria and seven were enrolled. Though the goal was to
identify patients with OI ≥15, in fact all infants had much
higher OIs at enrollment. All infants survived, and six of
the seven received ECMO; five of these received ECMO
within 24 hours of discontinuation of the study aerosol.
There were no serious adverse events. Acute deterioration
was documented in three infants in the IPGE1 groups 10
to 36 hours after start of study aerosol. There were system-
atic differences between the infants in the three groups;
most notably, infants in both of the IPGE1 groups hadduring study aerosol administration in control and combined
res represents control subjects. Dotted line with open circles
dose IPGE1). (a) Temperature; (b) Heart rate; (c) Mean blood pressure.
Table 3 Description of therapies prior to randomization, monitoring during aerosol administration, and outcomes of enrolled infants
Case
number
Before study aerosol During study aerosol After study aerosol
Surfactant Inotropes Pulmonary
vasodilators
Ventilator
Mode
Maximum
Temperature (°C)
Maximum
HR (bpm)
Minimum
MBP (mmHg)
Duration of study
aerosol (hours)
Was ECMO
provided?
Time to
ECMO
(hours)c
Neuroimaging at discharge
Control group:
2 Yes Dopamine Milrinone
Sildenafil
CMV 38.0 177 37 31.1 Yes 1.5 Normal study
4 Yes Dopamine Milrinone HFO 37.5 185 32 72 No Bilateral cephalhematomas,
thinning corpus callosum
5 No Dopamine
Dobutamine
- HFO 38.2 200 47 44.9 Yes 24.2 diffuse abnormality, white matter
signal ↑ on T2 weighted MRI
Low-dose IPGE1 group:
3 Yes Dopamine
Dobutamine
- HFO 33.6 131 46 10.1 Yes 1.5 Normal study
6 No - Milrinone HFO 30.6 118 43 36 Yes Not knowna Unknown
High-dose IPGE1 group:
1 Yes Dopamine
Dobutamine
- HFO 33.5 142 45 39.5 Yes 1.2 ↑ lactate peak suggestive of HIE
7b Yes Dopamine - CMV 33.7 121 63 34 Yes 4 Grade II IVH and posterior fossa
hemorrhage
CMV, conventional mechanical ventilation; HFO, high frequency oscillator.; HIE, hypoxic ischemic encephalopathy; IVH, intraventricular hemorrhage; MRI, magnetic resonance imaging; ↑, increased.
aInfant received ECMO at another institution, time of ECMO not known.
bInfant received low-dose IPGE1 for first 24 hours though randomized to high-dose IPGE1; thereafter switched to low-dose IPGE1.
cTime from stop of study aerosol to initiation of ECMO (hours).
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tion, an earlier age at presentation, and significantly lower
temperatures throughout the study aerosol administration.
The small sample size and clinical differences between the
three groups precludes any inference regarding the efficacy
of IPGE1 in PPHN.
The results of the two pilot RCTs reported in this
study highlight the substantial investments of capital,
human resources, technological expertise, and time in
evaluating emerging new therapies [30]. Planning for
these studies required performance of preclinical studies
mandated by the United States Food and Drug Adminis-
tration (FDA; addressing concerns about aerosol drug
delivery with various modes of neonatal ventilation and/
or INO; reaching consensus regarding patient manage-
ment protocols, eligibility criteria, definition of meaning-
ful outcome parameters, and use of nebulizer device in
the study; development of study documents, training of
site personnel, and obtaining IRB approvals.
The feasibility of conducting a large RCT was recog-
nized to be an important limitation as several interven-
tion clinical trials for NHRF were halted prematurely for
lack of enrollment [22-25]; thus pilot studies were
undertaken. Even though a survey of NRN sites between
2009 and 2010 suggested adequate numbers of patients
eligible for this study, the pilot studies identified that the
available patient population was very small. Foremost
among factors contributing to lack of feasibility of this
study was the decreased number of patients. This was
attributed to improved perinatal care practices leading
to decreased rates of both post-maturity and respiratory
morbidity, as well as improved results in NHRF with the
use of INO, surfactant, and HFOV [31,32]. It is likely
that with improved lung recruitment strategies, early use
of surfactant and optimal delivery of INO, the current
failure rate of INO may be considerably lower than that
quoted in the literature [33]. Secondly, the consent
process was challenging because of the short time win-
dow available, the high degree of stress parents’ experi-
enced, frequent administration of medications that affect
maternal cognition, and the lack of availability of parents
when infants were transferred to tertiary care centers
soon after birth for the management of PPHN.
The third factor that made these trials challenging was
the novel nature of the study intervention. These pilot
RCTs were the first trials of aerosolized selective pul-
monary vasodilators in critically ill neonates with NHRF.
The study protocol was complex and difficult to master
for investigative teams. At the time of inception of this
study, the MiniHeart low flow jet nebulizers were the
only FDA approved nebulizers available for use in neo-
nates; preliminary data were obtained using the Mini-
Heart nebulizer [26,12,34-38] and consequently the
protocol allowed the use of MiniHeart nebulizers only inthis study. Since then, ultrasonic and vibrating mesh neb-
ulizers have been developed and are increasingly being
used clinically [39,40]. As there are advantages and disad-
vantages associated with each aerosol device, studies are
needed to evaluate these devices for the delivery of IPGE1.
Another factor that contributed to the lack of feasibility
of these trials was the long time lapse between IRB ap-
proval and initiation of enrollment. As defined by feasibil-
ity criteria in the second pilot, 75% of centers were IRB
approved; however, readiness for study enrollment did not
coincide with IRB approval. This may be due to the need
for hospital approvals of research studies, as well as the
need for training of site nurses, respiratory therapists, and
pharmacists in implementing this novel intervention.
These studies highlight the challenges of performing
clinical trials in critically ill neonates with hypoxemic re-
spiratory failure. To date, only three interventions for
NHRF (ECMO, INO, and HFOV) have been shown in
large RCTs to significantly improve outcomes [4,41,42].
Objective evidence for other interventions for the treat-
ment of term NHRF is lacking. Although INO has revolu-
tionized outcomes, 40% of babies still do not respond, and
thus further therapeutic improvements are critical. Other
drugs, including sildenafil, inhaled iloprost, endothelin an-
tagonists, and antioxidants, are actively being explored for
the treatment of NHRF, but no large RCTs in critically ill
neonates have been reported. A failure to recruit patients
in this trial has important implications for other clinical
trials in this patient population. Inability to design defini-
tive clinical trials to evaluate newer therapies in NHRF will
propagate the practice of ‘off-label’ use of drugs that have
been approved for use in adults first [43]. From develop-
mental and metabolic standpoints, the disease processes
in children and their responses to therapies are very differ-
ent from those in adults [44]. The search for robust evi-
dence to guide the safe therapy of children and neonates
with pulmonary hypertensive vascular disease is crucial.
Important lessons can be learned from clinical trials in
adult and pediatric pulmonary hypertension where simi-
lar challenges with recruitment are encountered. The
prevalence of pulmonary hypertension in adults, chil-
dren, and neonates is insufficient to support formal
examination of all potential drug targets [45]. Recogniz-
ing the need for innovative approaches [43,46,47], a
workshop was established to consider alternative clinical
trial designs in pulmonary hypertension, in order to raise
the likelihood of new treatments reaching patients.
Acknowledging that classical sample size calculations
often lead to unrealistic expectations of the number of
subjects to be recruited, Offringa and van der Lee de-
scribed statistical and epidemiological aspects of small
sample approaches and emphasized the importance of
maximizing information obtained from the few subjects
enrolled [48]. Development of national and international
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tive approach. Clinical studies in pulmonary hyperten-
sion might be enhanced by a consortium approach that
utilizes the expertise of academic medicine, the treat-
ment initiatives of the pharmaceutical industry, and
study design from funding agencies interested in bio-
logical mechanisms [49]. To address this challenge, the
Pulmonary Hypertension Academic Research Consor-
tium was created as a forum to openly discuss strategies
for clinical trials in pulmonary hypertension that would
benefit all of the stakeholders. The goals of the consor-
tium were to establish consensus clinical endpoint defi-
nitions for future clinical trials, advance the conduct of
clinical research in the field, identify modern strategies for
clinical trials, and provide guidance to the pharmaceutical
industry to allow them to better identify and develop
treatments with the most promise. Similar approaches
need to be explored in NHRF.
Conclusions
In conclusion, there are important lessons to be learned
from the two pilot RCTs described in this report that
will be instrumental in designing future studies in this
critically ill population. The second pilot demonstrates
that it is possible to administer aerosols continuously in
the Neonatal Intensive Care Unit for extended periods
of time. When defining feasibility criteria, it needs to be
recognized that readiness to commence study enroll-
ment does not coincide with IRB approval. This lag
needs to be adjusted for in future clinical trials. In this
small sample size, there were no serious adverse events
reported with the two doses of IPGE1; future studies
should explore the efficacy of the higher dose and con-
sider dose escalation to identify the optimal therapeutic
dose. The second pilot also demonstrates that though
the goal was to identify patients with OI ≥15, in fact all
the babies had much higher OIs at enrollment as has
been shown in other RCTs in NHRF [4]. This suggests
that future trials randomize infants at an even earlier
stage, preferably at the time of initiation of INO. An-
other approach would be to randomize infants to pla-
cebo and treatments soon after PPHN is diagnosed, and
then add specific therapy, such as INO. Future studies
should allow the use of nebulizer devices approved by
the FDA for use in neonates with provision for a sub-
group analysis by the nebulizer device during the evalu-
ation of data. Ventilator strategy, use of supportive
therapies (such as surfactant and inotropes), and under-
lying cause of PPHN should be taken into account while
designing future studies. Both of the pilot trials reinforce
the challenges of performing RCTs in this critically ill
population of patients and the need for pragmatic study
designs reflective of the real-world situations with a real-
istic timeline.Additional file
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